WST on NYSE

West Pharmaceutical Services UK

American surgical and medical instruments and apparatus company.1

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with MiniMed Group, Inc., Globus Medical or Insulet (United States), or pick any stock.

  • TickerWST on NYSE1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersPA1
  • Incorporated inPA3
  • Business address530 Herman O. West Drive, Exton, Pa 193413
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

35.9%Gross margin4
19.0%Operating margin4
16.1%Net margin4
6.3%Revenue growth, 20254
15.5%Return on equity4
0.06×Debt to equity4
$468.9MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Proprietary Products brought in 81% of the revenue West Pharmaceutical Services UK broke down this way in fiscal 2025.

  1. Proprietary Products$2.5B481%up 7% from 2024
  2. Contract Manufactured Products$582.0M419%up 4% from 2024
Business segments by year
Business segments202320242025
Proprietary Products$2.4B$2.3B$2.5B
Contract Manufactured Products$552.5M$558.7M$582.0M

Regions

United States brought in 43% of the revenue West Pharmaceutical Services UK broke down this way in fiscal 2025.

  1. United States$1.3B443%up 8% from 2024
  2. Other Europe Countries$451.0M415%up 17% from 2024
  3. Germany$380.3M412%up 2% from 2024
  4. Other Countries$353.3M411%up 4% from 2024
  5. I E$333.3M411%up 3% from 2024
  6. France$226.6M47%down 6% from 2024
Regions by year
Regions202320242025
United States$1.2B$1.2B$1.3B
Other Europe Countries$388.1M$385.5M$451.0M
Germany$406.1M$372.5M$380.3M
Other Countries$348.5M$339.0M$353.3M
I E$285.7M$323.2M$333.3M
France$282.9M$242.2M$226.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue64¢$2.0B
  • Research and development2¢$74.3M
  • Selling, general and admin13¢$393.6M
  • Other costs1¢$20.8M
  • Income tax4¢$121.6M
  • Profit16¢$493.7M

Out of $3.1B in revenue.4

Where each dollar of operating cash went, fiscal 2025

  • Capital spending38¢$285.9M
  • Dividends paid8¢$61.2M
  • Share buybacks18¢$134.0M
  • Kept or used elsewhere36¢$273.7M

Out of $754.8M of cash from operations.4

Financial statements

Revenue56784$3.1B in 2025+67% since 2019
0$1.0B$2.0B$3.0B$4.0B2019: $1.8B$1.8B20192020: $2.1B$2.1B2020+17%2021: $2.8B$2.8B2021+32%2022: $2.9B$2.9B2022+2%2023: $2.9B$2.9B2023+2%2024: $2.9B$2.9B2024−2%2025: $3.1B$3.1B2025+6%
Gross profit56784$1.1B in 2025+82% since 2019
0$500.0M$1.0B$1.5B2019: $605.7M$605.7M20192020: $767.8M$767.8M2020+27%2021: $1.2B$1.2B2021+53%2022: $1.1B$1.1B2022−3%2023: $1.1B$1.1B2023−1%2024: $998.5M$998.5M2024−12%2025: $1.1B$1.1B2025+11%
Operating income56784$584.9M in 2025+97% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $296.6M$296.6M20192020: $406.9M$406.9M2020+37%2021: $752.3M$752.3M2021+85%2022: $734.0M$734.0M2022−2%2023: $676.0M$676.0M2023−8%2024: $569.9M$569.9M2024−16%2025: $584.9M$584.9M2025+3%
Net income56784$493.7M in 2025+104% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $241.7M$241.7M20192020: $346.2M$346.2M2020+43%2021: $661.8M$661.8M2021+91%2022: $585.9M$585.9M2022−11%2023: $593.4M$593.4M2023+1%2024: $492.7M$492.7M2024−17%2025: $493.7M$493.7M2025+0%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Net sales$3.1B$2.9B$2.9B
Cost of goods and services sold$2.0B$1.9B$1.8B
Gross profit$1.1B$998.5M$1.1B
Research and development$74.3M$69.1M$68.4M
Selling, general and administrative expenses$393.6M$338.5M$353.4M
Other expense (income) (Note 16)$51.2M$21.0M$31.4M
Operating profit$584.9M$569.9M$676.0M
Interest expense$500.0K$3.0M$9.0M
Interest income-$17.5M-$19.6M-$28.0M
Other nonoperating expense (income)$1.0M$1.0M-$3.0M
Income before income taxes and equity in net income of affiliated companies$600.9M$585.5M$698.0M
Income tax expense$121.6M$107.5M$122.3M
Equity in net income of affiliated companies-$14.4M-$14.7M-$17.7M
Net income$493.7M$492.7M$593.4M
Basic (in dollars per share)$6.83$6.75$7.98
Diluted (in dollars per share)$6.79$6.69$7.88
Basic (in shares)72.3M shares73.0M shares74.3M shares
Diluted (in shares)72.7M shares73.7M shares75.3M shares

Compare West Pharmaceutical Services UK with another company

Leadership

Who has led West Pharmaceutical Services UK, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Donald E. Morel Jr.2006–2015
  2. Eric Mark Green2015–2026
  3. Michel Lagarde2026–now

Chair

  1. Donald E. Morel Jr.2006–2015
  2. Eric Mark Green2023–now

President

  1. Steven A. Ellers2006–2011
  2. Donald A. McMillan2006–2012
  3. Robert S. Hargesheimer2006–2009
  4. Heino Lennartz2009–2016
  5. John E. Paproski2010–2016
  6. Karen Flynn2012–2016
  7. Warwick Bedwell2012–2016
  8. Christopher G. Ryan2015–2016
  9. Eric Mark Green2016–2026
  10. Michel Lagarde2026–now

Chief financial officer

  1. William J. Federici2006–2018
  2. Bernard Birkett2018–2025
  3. Robert W. McMahon2025–now

Chief operating officer

  1. Steven A. Ellers2006–2011
  2. Matthew T. Mullarkey2008–2009
  3. Bernard Birkett2022–2023
2010201520202025
Board members and other officers (44)

Subsidiaries and ownership

Parent company

From Wikidata.1

Former names

  • WEST CO INCApr 5, 1994 to Feb 11, 19993

Timeline

  1. Sep 10, 2026New chief executive Michel Lagarde becomes CEO12
  2. Apr 27, 2015New chief executive Eric Mark Green becomes CEO13
  3. Jan 3, 2006New chief executive Donald E. Morel Jr. becomes CEO14

Filings

312 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 46 major events, 193 insider forms, 15 large holders, 38 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Sep 15, 20264 EDGAR
  3. Sep 10, 20264 EDGAR
  4. Sep 10, 20264 EDGAR
  5. Sep 10, 20263 EDGAR
  6. Aug 12, 20264 EDGAR
  7. Aug 6, 2026SCHEDULE 13G EDGAR
  8. Jul 23, 202610-Q EDGAR
  9. Jul 23, 20268-K EDGAR
  10. Jul 14, 20268-K EDGAR
  11. Jul 1, 20264 EDGAR
  12. Jun 1, 20268-K EDGAR
  13. May 20, 20268-K/A EDGAR
  14. May 14, 20264 PRIMARY DOCUMENT EDGAR
  15. May 13, 2026SD EDGAR
  16. May 11, 20268-K EDGAR
  17. May 7, 2026144 EDGAR
  18. May 6, 20264 PRIMARY DOCUMENT EDGAR
  19. May 6, 20264 PRIMARY DOCUMENT EDGAR
  20. May 6, 20264 PRIMARY DOCUMENT EDGAR

The 312 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 15 such filings since October 2021, the latest 10:

  1. Aug 6, 2026SCHEDULE 13G
  2. Apr 30, 2026SCHEDULE 13G
  3. Apr 29, 2026SCHEDULE 13G
  4. Mar 27, 2026SCHEDULE 13G/A
  5. Oct 31, 2025SCHEDULE 13G/A
  6. Feb 13, 2024SC 13G/A
  7. Jan 24, 2024SC 13G/A
  8. Feb 14, 2023SC 13G/A
  9. Feb 9, 2023SC 13G/A
  10. Jan 24, 2023SC 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.6,651,784$2.4B0.0%−184,930
Vanguard Capital Management LLC4,613,134$1.7B0.0%−70,152
Vanguard Portfolio Management LLC4,015,766$1.4B0.1%−78,243
Fmr LLC3,574,816$1.3B0.1%+2,325,068
State Street Corp3,348,698$1.2B0.0%+54,920
Artisan Partners Limited Partnership2,411,792$865.8M1.4%−246,101
Bank of New York Mellon Corp2,043,823$733.7M0.1%−422,035
Generation Investment Management Llp2,028,322$728.2M7.1%−215,654
Geode Capital Management, LLC1,903,279$680.6M0.0%−9,176
Morgan Stanley1,582,546$568.1M0.0%+124,264
Jpmorgan Chase & Co1,164,527$413.0M0.0%+121,110
Brown Advisory Inc1,075,309$386.0M0.6%−265,568
Longview Partners (Guernsey) LTD1,033,826$371.1M6.0%−281,577
Invesco Ltd.1,009,852$362.5M0.0%−46,155
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC884,865$317.7M0.1%−17,899
Norges Bank862,915$309.8M0.0%New
Goldman Sachs Group Inc814,772$292.5M0.0%+87,155
Kayne Anderson Rudnick Investment Management LLC760,622$273.1M0.8%−97,676
TD Asset Management Inc731,054$262.4M0.2%−37,899
Northern Trust Corp709,421$254.7M0.0%−21,862
Capital Research Global Investors609,221$218.7M0.0%+5,210
Van Eck Associates Corp604,754$217.1M0.1%−108,825
ProShare Advisors LLC598,024$214.7M0.3%−62,060
Findlay Park Partners LLP596,646$214.2M2.9%−20,120
Charles Schwab Investment Management Inc583,984$209.7M0.0%+29,652

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

12 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jul 22, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000−52.2%Report
Jun 17, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000+46.5%Report
Apr 8, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000−45.7%Report
Feb 25, 2025Robert P. Bresnahan, Jr.Republican, HouseBuy$1,001 - $15,000+44.1%Report
Feb 13, 2025Jared MoskowitzDemocratic, HouseSale$1,001 - $15,000−65.8%Report
Nov 8, 2024Jared MoskowitzDemocratic, HouseSale$1,001 - $15,000+10.8%Report
Dec 28, 2023Jared MoskowitzDemocratic, HouseBuy$1,001 - $15,000−54.0%Report
Jul 14, 2023Jared MoskowitzDemocratic, HouseBuy$1,001 - $15,000−72.3%Report
Mar 30, 2022Tommy TubervilleRepublican, SenateSale$1,001 - $15,000+76.6%Report
Mar 29, 2021Tommy TubervilleRepublican, SenateBuy$1,001 - $15,000−58.5%Report
Sep 24, 2020Greg Gianforte, HousePartial sale$50,001 - $100,000+93.3%Report
Jun 24, 2019Donna Shalala, HouseSale$1,001 - $15,000−50.6%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72